The quality of evidence is downgraded due to study limitations (selection bias and attrition bias).
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias «Additional comments for included studies...»2 |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis | |||||
| «Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011 CONQUER-study |
Multicenter RCT | Adults aged 18-70 years with BMI 27-45 kg/m2 and two or more obesity-related comorbidities (hypertension, dyslipidemia, diabetes or prediabetes, abdominal obesity). | Three groups: Placebo, phentermine+topiramate 7.5/46 mg, phentermine+topiramate 15/92 mg. Oral administration. All groups received lifestyle counseling |
Percentage change in bodyweight and proportion of patients achieving at least 5% weight loss at 56 weeks | Low |
| «Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011 SEQUEL-study |
Multicenter RCT Follow-up study to Gadde et al. |
Adults with BMI 27–45 kg/m² and ≥2 obesity-related comorbidities (hypertension, dyslipidemia, diabetes, abdominal obesity). | Three groups: Phentermine/topiramate 7.5/46 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling. | Percentage change in bodyweight and proportion of patients achieving ≥5%, ≥10%, ≥15% weight loss at 108 weeks | Moderate |
| «Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011 EQUIP-study |
Multicenter RCT | Adults 18–70 years with severe obesity BMI ≥35 kg/m². | Three groups: Phentermine/topiramate 3.75/23 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling including a 500 kcal/day energy deficit. | Percentage change in bodyweight and proportion of patients achieving ≥5%, ≥10%, ≥15% weight loss at 56 weeks | Moderate |
| Reference | Comments |
|---|---|
| «Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 | CONQUER-study. High number of dropouts (31%), but results were similar in ITT and sensitivity analyses across groups. Weight loss results were similar regardless of comorbidity. Industry funded. |
| «Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 | SEQUEL was a 52-week double-blind, placebo-controlled extension of the CONQUER trial, conducted at 36 of 93 U.S. sites chosen for high participant retention and enrollment. Participants remained in their original randomized groups (placebo or phentermine/topiramate 7.5/46 mg or 15/92 mg), for a total treatment duration of 108 weeks. Randomization was stratified by sex and type 2 diabetes status. Of the 866 CONQUER completers at eligible sites, 676 (78%) enrolled in SEQUEL (69% placebo, 79% 7.5/46 mg, 86% 15/92 mg), and 84% completed it. The modified ITT population included participants with at least one dose and one post-baseline weight measurement. The effect size may be somewhat overestimated, as participants who continued were possibly more motivated and adherent. Industry funded. |
| «Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 | Double-blinded, placebo-controlled, multicenter RCT. High dropout rate (placebo 47.1%, low dose 39.0%, high dose 33.6%) raising attrition bias concern. Primary ITT-analysis included all randomized patients who received at least one dose of drug/placebo and had at least one post-randomization weight measurement. Of the participants 83% were females. Industry funded. |
Results
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Weight loss in kg:s mean, (%) I | Weight loss in kg:s mean, (%) C | Estimated difference: (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: moderate. The quality of evidence is downgraded due to study limitations
(selection bias and attrition bias). I= intervention; C=comparison; CI=confidence interval |
|||||
| «Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011 | I: 7.5/46mg N=488 15/92mg N=981 C: placebo N=979 |
56 weeks | 7.5/46mg: -8.1 kg (-7.8%) 15/92mg: -10.2 kg (-9.8%) |
Placebo: -1.4kg (-1.2%) |
7.5/46 mg: -6.6% (-7.4 to -5.8) 15/92mg: -8.6% (-9.3 to -8.0) |
| «Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011 | I: 7.5/46 mg N=153, 15/92mg N=295 C: placebo N=227 |
108 weeks | 7.5/46 mg: -9.6 kg (–9.3%) 15/92 mg: -10.9 kg (–10.5%) |
Placebo: -2.1 kg (-1.8%) |
7.5/46 mg: –7.5 % 15/92 mg: –8.7 % |
| «Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011 | I: 15/92mg N=498, C: placebo N=498 |
56 weeks | 15/92 mg: -10.9% (-10.2-11.7%) |
Placebo: -1.6% (-0.8-2.3%) |
15/92 mg: -9.3 % |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Odds ratio (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: moderate. The quality of evidence is downgraded due to study limitations
(selection bias and attrition bias). I= intervention; C=comparison; CI=confidence interval |
|||||
| «Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»1 Gadde et al. 2011 | I: 7.5/46mg N=488 15/92mg N=981 C: placebo N=979 |
56 weeks | 5% weight loss: 7.5/46 mg: 303 (62%) 15/92mg: 687 (70%) |
5% weight loss: 204 (21%) |
6.3 (4.9-8.0) 9.0 (7.3-11.1) |
| 10% weight loss: 7.5/46 mg: 182 (37%) 15/92mg: 467 (48%) |
10% weight loss: 72 (7%) |
7.6 (5.6-10.2) 11.7 (8.9-15.4) |
|||
| «Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»2 Garvey et al. 2011 | I: 7.5/46 mg N=153, 15/92mg N=295 C: placebo 227 |
108 weeks | 5% weight loss: 7.5/46 mg: 75.2% 15/92 mg: 79.3% |
5% weight loss: 30.0% |
- |
| 10% weight loss: 7.5/46 mg: 50.3% 15/92 mg: 53.9 % |
10% weight loss: 11.5% | ||||
| 15% weight loss: 7.5/46 mg: 24.2% 15/92 mg: 31.9% |
15% weight loss: 6.6% | ||||
| «Allison DB, Gadde KM, Garvey WT, et al. Controlled...»3 Allison et al. 2011 | I: 15/92mg N=498, C: placebo N=498 |
56 weeks | 5% weight loss: 15/92mg: 332 (66.7%) |
5% weight loss: 83 (17.3%) |
- |
| 10% weight loss: 15/92mg: 235 (47.2%) |
10% weight loss: 37 (7.4%) |
||||
| 15% weight loss: 15/92mg: 161 (32.3% ) |
15% weight loss 17 (3.4%) |
||||